Background-Sex-specific differences affect the evaluation, treatment, and prognosis of coronary artery disease. We tested the hypothesis that long-term outcomes of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) are different between women and men. Methods and Results-Consecutive 1090 patients, referred for PCI and undergoing FFR measurements at the Mayo Clinic between October 2002 and December 2009, were included in this registry study. Clinical events were compared between the sexes during a median follow-up of 50.9 months. Of all patients, women had higher FFR adjusted by visual coronary stenosis than men (P=0.03). The Kaplan-Meier percent of major adverse cardiac events at 5 years was 35% in women and 38% in men (P=0.54). Interestingly, in patients undergoing PCI with an FFR <0.75, the incidence of death or myocardial infarction was significantly higher in women than in men (hazard ratio, 2.16; 95% confidence interval, 1.04-4.51; P=0.04). Moreover, compared with patients with FFR >0.80, deferral of PCI for those with FFR between 0.75 and 0.80 was associated with an increased rate of major adverse cardiac events, particularly death or myocardial infarction in women (hazard ratio, 3.25; 95% confidence interval, 1.56-6.74; P=0.002) and revascularization in men (hazard ratio, 2.66; 95% confidence interval, 1.66-4.54; P<0.001). Conclusions-Long-term outcome differs between women and men undergoing FFR-guided PCI. Our data suggest that the sex-based treatment strategy is necessary to further optimize prognosis of patients with coronary artery disease. (Circ Cardiovasc Interv. 2013;6:662-670.)
S ex-specific differences can affect the evaluation, treatment, and prognosis of coronary artery disease (CAD). 1, 2 For 3 decades, there has been a debate about sexbased differences in benefits from coronary revascularization, with inconsistent results between studies. Although earlier data suggested that women who undergo percutaneous coronary intervention (PCI) would experience more procedural complications and worse prognosis, [3] [4] [5] more recent studies do not support sex-based differences in longterm outcomes after revascularization. [6] [7] [8] [9] [10] [11] [12] [13] Moreover, some studies report more favorable long-term PCI outcomes in women than in men. [14] [15] [16] [17] Notably, in previous studies, the decision making for revascularization was usually based on coronary angiography, which can fail to provide an accurate and reproducible measure of the hemodynamic significance of a stenosis. 18 Therefore, although the goal of PCI is to relieve ischemia and improve symptoms, it is inevitable, with an angiographyguided strategy, to have revascularization of lesions that are of no hemodynamic relevance and vice versa, deferred PCI of hemodynamically significant stenoses.
Fractional flow reserve (FFR), a validated index of the physiological significance of a coronary stenosis, is defined as the ratio of maximal blood flow in a stenotic artery to theoretical normal maximal flow. 19 An FFR of <0.75 identifies a lesion that is associated with ischemia. 20 When the decision to perform PCI is based on FFR, favorable longterm outcome has been demonstrated in recent studies, [21] [22] [23] [24] as compared with angiography-guided PCI or optimal medical therapy alone. Nevertheless, data about sex-specific differences in FFR are scarce. Recently, a Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) substudy evaluated for the first time the impact of sex differences on FFR-guided PCI and demonstrated an equal benefit in women and men during 2-year follow-up. 25 However, it is still unclear whether the long-term outcome after FFR-guided treatment is comparable between women and men.
The aim of this study was to test the hypothesis that prognosis of CAD differs between sexes. We, therefore, compared the long-term outcome between women and men in whom the intervention strategy was based on FFR.
Methods

Study Population
In this retrospective study, consecutive patients with measurements of the FFR at the Mayo Clinic between October 2002 and December 2009 were included. Exclusion criteria were (1) presentation with acute myocardial infarction (MI) or cardiogenic shock or emergency PCI, (2) referral for coronary artery bypass surgery, and (3) declined use of medical records for research purposes. Medical records of all patients were reviewed to obtain baseline information. Angiographic appearances were assessed visually. The study was approved by the institutional review board of the Mayo Clinic.
Intracoronary Pressure Measurements
Intracoronary pressure measurement was performed using a 0.014in pressure-monitoring guide wire (Pressure Wire, Radi Medical, Uppsala, Sweden, or Wave Wire, Volcano, Rancho Cordova, CA). The pressure wire was introduced via a guiding catheter, calibrated, and advanced into the coronary artery distal to the assessed stenosis as described previously. 19 Doses up to 72 μg of intracoronary adenosine or intravenous adenosine at a rate of 140 μg/kg per minute were administered to achieve maximal coronary blood flow. FFR was calculated as the ratio of the mean distal (trans-stenotic) coronary pressure measured by the pressure wire to mean aortic pressure measured by the guiding catheter at maximal hyperemia.
Generally, PCI was performed in patients with FFR <0.75 and deferred in those with FFR >0.8. For FFR values ranging between 0.75 and 0.80, the decision was left to the operator's discretion.
Clinical Follow-up
Patients with PCI were tracked via telephone calls at 6 months, 12 months, and annually thereafter. Hospital records were obtained and reviewed on follow-up to record follow-up events. Patients with PCI deferred (and no prior PCI) were contacted via a single questionnaire and medical records review.
Clinical outcomes after PCI were compared between women and men. Major adverse cardiac event (MACE) was defined as composite of death, MI, and any repeat revascularization. Death encompassed all-cause mortality. MI was defined as (2 of 3 criteria) prolonged chest pain >20 minutes, levels of serum creatine kinase (or the MB fraction) >2-fold higher than the upper normal limit, and ST-T segment changes or new Q waves on serial ECG indicative of myocardial damage. 26 Revascularization was defined as any clinically driven revascularization including bypass surgery.
Statistical Analysis
Continuous variables are summarized as either mean±SD or median (first-third quartiles [Q1-Q3]). Group comparisons for these variables are tested using Student 2-sample t test or the Wilcoxon ranksum test, respectively. Discrete data are presented as frequency and group percentage and are tested with Pearson χ 2 test if categorical and the rank-sum test if ordinal. Kaplan-Meier methods are used to estimate survival in time-to-event variables, with the log-rank test used for group comparisons. Follow-up began after discharge and did not include in-hospital events. The adjusted association between sex and FFR measure was conducted using a mixed linear regression model. A random effect was used to account for correlation between measures of >1 vessel on the same patient; all other effects were modeled as fixed. Cox multiple regression models were used to estimate hazard ratios (HRs) for follow-up events. To investigate differential effects between men and women and those with and without PCI, the following 2-way interaction terms were included: sex and FFR, sex and PCI treatment, FFR and PCI treatment. Age, hypertension, body mass index, history of cholesterol >240 mg/dL, smoking history, diabetes mellitus, and ejection fraction were included as covariates and were selected based on clinical relevance. All significance tests were 2 tailed with a 0.05 significance level. All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC).
Results
Baseline Characteristics
A total of 1090 patients (407 [37%] women, 683 [63%] men) were eligible for analyses. Generally, women were older (67.2±11.5 versus 64.8±11.2 years; P<0.001), had fewer smokers (11.3% versus 13.8%; P<0.001), a lower incidence of prior MI (20.1% versus 27.5%; P=0.02) or coronary artery bypass grafting (8.1% versus 14.3%; P=0.002), and less angiographic lesion severity as compared with men. Patient characteristics in each FFR subset are shown in Tables 1 and 2 . Particularly, left ventricular mass index was lower in women than in men. Lesion length and vessel size were similar in women and men. Information about PCI and in-hospital outcomes is shown in Tables 3 and 4. Figure 1 shows the comparison of FFR values within each subset of angiographic percent diameter stenosis (<60%, 60%-69%, 70%-79%, 80%-89%, and ≥90%) between women and men. After adjusting for patient characteristics (age, vessel
Comparison of FFR Values Between Sexes
WHAT IS KNOWN
• Women have smaller epicardial vessel size, less severe stenosis, and a higher incidence of microvascular disease compared with men.
• Fractional flow reserve-guided percutaneous coronary intervention has advantages compared with angiography-guided treatment in intermediate lesions.
• Data about sex-specific differences in fractional flow reserve are scarce.
WHAT THE STUDY ADDS
• Women may have higher fractional flow reserve than men with similar stenosis severity.
• Women had higher risk of death/myocardial infarction than men when percutaneous coronary intervention was performed for lesions with a fractional flow reserve <0.75.
• Deferring percutaneous coronary intervention in a lesion with fractional flow reserve ranging between 0.75 and 0.80 may cause more hard events in women than in men.
locations, stenosis level, hypertension, smoking status, prior MI, prior coronary artery bypass grafting, and renal function), the overall FFR in women was 0.011 points higher than in men (P=0.03). When lesions were categorized into <60%, 60% to 69%, 70% to 79%, 80% to 89%, and ≥90% diameter stenosis, FFR values were significantly higher in women than in men only for lesions with 60% to 69% stenosis (mean, 0.021; P=0.03) and 70% to 79% stenosis (mean, 0.039; P=0.002).
Long-term Outcomes After FFR-Guided Treatment Strategy
Follow-up was available in 965 patients (88.5% overall, 89% of women, 88% of men). The median (Q1-Q3) lengths of follow-up were 49.6 (26.6-70.5) months in women and 46.1 (22.0-69.4) months in men (P=0.35). The unadjusted Kaplan-Meier 5-year estimates of MACE (35% versus 38%; P=0.54; Figure 2 ), mortality (15% versus 14%; P=0.84), repeat revascularization (22% versus 27%; P=0.32), and death or MI (19% versus 20%; P=0.72) were similar in women and men.
In a Cox proportional hazard model, women with an FFR of <0.75 had a significantly higher incidence of death or MI after PCI, as compared with men (HR, 2.16; 95% confidence interval [CI], 1.04-4.51; P=0.04). In patients with FFR ≥0.75, the incidence of MACE and death/MI were similar in women and men, regardless of whether PCI was performed ( Table 5) .
Compared with patients with FFR >0.80, those in whom PCI was deferred with an FFR between 0.75 and 0.80 had a significantly higher rate of MACE in both women (HR, 2.12; 95% CI, 1.23-3.65; P=0.007) and men (HR, 2.16; 95% CI, 1.39-3.34; P=0.001). This increased rate of MACE was driven by a higher incidence of death or MI in women (HR, 3.25; 95% CI, 1.56-6.74; P=0.002) and a higher incidence of repeat revascularization in men (HR, 2.66; 95% CI, 1.66-4.54; P<0.001; Figure 3 ).
Discussion
In this study, we analyzed the relationship between sex and outcomes in patients undergoing FFR-guided CAD management. Three main findings are as follows: (1) FFR values were higher in women than in men after corrected for visually assessed coronary anatomic severity; (2) although no sexrelated difference in outcome was found in patients with FFR >0.75, women had higher risk of death/MI than men when PCI was performed for lesions with an FFR <0.75; and (3) the deferral of PCI in lesions with FFR between 0.75 and 0.80 was associated with an increased rate of death or MI in women and increased rate of repeat revascularization in men.
In measurements of FFR, the majority was given intracoronary adenosine, and higher FFR values for similar angiographic stenoses were found in women compared with men. This result is consistent with the FAME substudy in which adenosine was administered intravenously. 25 It has been reported that age, left ventricular hypertrophy, lesion length, and vessel size may influence the FFR. 25, 27, 28 It could have also been explained by the fact that women are more likely to have impaired coronary microvascular reactivity to adenosine than the men, [29] [30] [31] resulting in higher FFR. This finding suggests that it may be reasonable to consider a sex-specific cutoff point of FFR for those patients in whom the FFR value approaches 0.80.
Sex-related differences in outcomes after angiographyguided coronary revascularization have been explored extensively. Higher risk profile, more comorbidities, smaller vessel size, and referral bias may yield an unfavorable prognosis of women undergoing revascularization in early data, whereas advances in technology, device, medical therapy, and patient selection may be contributing factors for improved outcomes in women with PCI. 9, 10, 12 An AHA Scientific Statement suggests that risks and benefits are similar for men and women after intervention. 32 As for the FFR-guided treatment, our data showed a higher incidence of death or MI in women undergoing PCI in a vessel with FFR <0.75, as compared with men. This result is inconsistent with a recent substudy of the FAME study, 25 which reported a comparable 2-year outcome after PCI in women and men. Three factors might be associated with this disagreement. First, the threshold of FFR to perform PCI is different in our study and the FAME study. Second, differences in outcome might be more prominent during the longer follow-up in the current study. Third, the observed sex-related differences might have been somewhat overestimated attributable to the relatively lower number in subgroups of the current study.
Previous studies reported women receive relatively less symptom relief with PCI compared with men, suggesting that ischemia induced by multiple mechanisms may serve as a source for symptoms and is an important determinant of outcome in women. 33, 34 Recently, the Women's Ischemia Syndrome Evaluation (WISE) study demonstrated that a limited coronary microvascular response to adenosine was associated with increased risk for major adverse events in women. 35 Moreover, several studies indicate that microvascular disease may play a more prominent role for prognosis in women with CAD. 34, [36] [37] [38] [39] As such, ischemia caused by microvascular disease might result in unfavorable outcome in women undergoing PCI. Interestingly, our data showed that the sex-related difference was only observed among patients with an FFR <0.75. We therefore postulate that hemodynamically significant stenosis in epicardial coronary arteries is associated with greater microvascular dysfunction in women. Further studies are needed to verify this theory, especially focusing on clarification of the pathophysiology of ischemic heart disease and identification of new targets for therapeutic intervention for women.
In the current study, a considerable number of patients were deferred from PCI after FFR assessment and were treated medically. The FAME 2 study reported that FFRguided treatment strategy plus the best available medical therapy was associated with better outcomes, as compared with the best available medical therapy alone. 22 However, there was significant sex bias identified previously in the use of evidence-based medical therapy, 40 and whether this bias may have an influence on outcome after FFR-guided treatment is unclear. In the present study, event rates were comparable between women and men in whom PCI were deferred based on FFR. This result is consistent with a recent report supporting that differences between sexes diminish and outcomes improve with broader use of effective evidence-based medical therapies. 41 The FFR values between 0.75 and 0.80 are regarded as a gray zone, and decision making for revascularization requires clinical judgment. More recent studies adapted the upper limit of this small transition zone as a threshold of PCI to limit the number of ischemic lesions left untreated. 21, 42 The current study demonstrates that deferring PCI in lesions with an FFR ranging between 0.75 and 0.80 might indeed result in worse outcomes, consistent with a prior study. 43 Interestingly, the higher rate of MACE was driven by more hard events (death or MI) in women and by more revascularizations in men. Two mechanisms may partly account for this finding. First, some women with an actual FFR of <0.75 and potentially worse outcome could have been misclassified to the higher FFR subset (0.75-0.80) attributable to submaximal hyperemia and deferred from PCI. Second, men with deferral of PCI were more likely to undergo revascularization in the follow-up attributable to more severe angiographic stenosis, as compared with women in the same FFR subset.
Limitations
This single-center, observational study has limitations inherent to nonrandomized trials. It was performed in a nonselected population of everyday practice with differences in baseline characteristics and involved multiple operators. We did not adjust reported P values for multiple hypothesis tests. Because the overall type I error rate for the study may be >0.05, our results may need confirmation in future studies. Moreover, women were significantly older than men in the overall population. The age difference could not be fully adjusted statistically and might have an influence on outcome, probably in favor of men. This may not diminish the robust results but could contribute to an overestimation of the outcome gap between women and men.
In this study, we observed higher FFR values in stenoses of ≥90% than in 70% to 89% stenoses. Although 4% of those with 91% to 99% of visual stenoses do not have significant functional relevance (FFR >0.80) in the FAME study, 44 it may reflect selection bias in this study. In routine In women and men with <60%, 60% to 69%, 70% to 79%, 80% to 89%, and ≥90% stenoses, the median FFR were 0.90 and 0.89, 0.85 and 0.84, 0.79 and 0.77, 0.78 and 0.76, and 0.84 and 0.79, respectively. After adjustment for covariates, FFR values were significantly higher in women than in men only for lesion with 60% to 69% diameter stenosis (mean, 0.021; P=0.03) and 70% to 79% (mean, 0.039; P=0.002) diameter stenosis. The edges of the blue boxes are the 25th and 75th percentiles (Q1, Q3), respectively; the lines inside the blue boxes represent the median values; the blue diamonds on the plot are the means; the upper and lower bars outside the blue boxes represent the maximum and minimum values, the green diamonds represent the adjusted means of FFR, respectively. F indicates female; and M, male.
practice, operators rarely decide to measure FFR for a stenosis of >90%. Nevertheless, it is possible that some stenoses of >90% seem not to be so flow limiting on angiography appearance that operators decide to perform a functional assessment. Another explanation for a high value of FFR in the presence of an apparently very tight stenosis is the presence of abundant collaterals or an artery perfusing a small amount of myocardium, such as an infracted area, 45 but this is not routinely assessed.
Patients received escalating doses of adenosine up to 72 µg in this study until maximal hyperemia and the lowest FFR were achieved. Nevertheless, López-Palop et al 46 recently reported that an intracoronary bolus dose >300 μg could be equal to or more effective than an intravenous infusion of adenosine in achieving maximum hyperemia when calculating the FFR. Therefore, the dose of intracoronary adenosine used in this study might be too low, resulting in misclassification for some patients. The coronary stenoses were assessed visually, rather than by quantitative coronary angiography or intravascular ultrasound.
Conclusions
This study observed that female patients undergoing FFRguided PCI have less favorable long-term outcome than their male counterparts. Consideration should be given to the sexbased therapeutic target and treatment strategy to further optimize clinical outcomes of patients with CAD, especially for women.
